3 POST-DOCTORAL OR JUNIOR (BSc or MSc)/SENIOR (PhD) SCIENTIST POSITIONS – Laboratory of Dr. H. Uri Saragovi
Nous vous partageons l’information envoyée par l’institution. Afin de maintenir l’intégrité de leur message, nous avons décidé de garder le texte original anglais.
INSTITUT LADY DAVIS
The Lady Davis Institute for Medical Research (LDI) opened its doors in 1969, some 30 years after the founding of its parent institution, Montreal’s world-renowned Jewish General Hospital (JGH). Over the years, the LDI has been remarkably successful in attracting outstanding investigators with national and international reputations. Special areas of interest include Cancer Therapeutics, Molecular Oncology, Cell and Gene Therapy, AIDS/HIV, Aging, Hypertension and Cardiovascular Disease, Clinical Epidemiology, and Psychosocial Aspects of Disease. The LDI is one of the most productive hospital-based research institutes in Canada and Quebec in terms of peer-reviewed grant funding per square feet.
3 POST-DOCTORAL OR JUNIOR (BSC OR MSC)/SENIOR (PHD) SCIENTIST POSITIONS – LABORATORY OF DR. H. URI SARAGOVI
FOCUS AREAS: NEURODEGENERATION – NEUROPROTECTION
- Chemical Biology & Drug Development
- Receptor Pharmacology (ex vivo and in vivo)
- Molecular Basis of Therapeutics
- Pre-clinical and Translational Medicine
We are looking for highly motivated postdoc and/or junior scientists to join a Team of local and international collaborators on Neurotrophin Receptors and Signaling, mechanisms of disease, target validation, and experimental therapeutics.
Scientific programs ranging from basic discovery to Investigational New Drugs. Role expected in producing high quality scientific publications, interest in patents is a plus. Follow-on career opportunities in industry if interested.
Description postdoctoral positions
Description research staff positions
PR H. URI SARAGOVI
Research in my laboratory focuses on understanding macromolecular structure function relationships, particularly in receptor-ligand interactions.
We have contributed towards the development of protein mimicry technology (reviewed in Nature Biotechnology, 10: 773; Immunomethods 1: 3-12). Using molecular design, biochemistry, and molecular biology techniques large proteins may be dissected to their smallest functional units. These approaches can be adapted for rational drug design and the development of agonists and antagonists.